Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
4.150
-0.010 (-0.24%)
At close: Jun 27, 2025, 4:00 PM
4.130
-0.020 (-0.48%)
After-hours: Jun 27, 2025, 7:25 PM EDT
Verastem Employees
Verastem had 78 employees as of December 31, 2024. The number of employees increased by 5 or 6.85% compared to the previous year.
Employees
78
Change (1Y)
5
Growth (1Y)
6.85%
Revenue / Employee
$128,205
Profits / Employee
-$1,908,679
Market Cap
228.04M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
VSTM News
- 1 day ago - Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers - Seeking Alpha
- 3 days ago - Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - Business Wire
- 26 days ago - Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor - Business Wire
- 4 weeks ago - Verastem Oncology to Present at the Jefferies Global Healthcare Conference - Business Wire
- 5 weeks ago - Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma - Business Wire
- 5 weeks ago - Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - Business Wire
- 6 weeks ago - Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates - Business Wire
- 7 weeks ago - FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer - Business Wire